| Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients H Sokol, B Pigneur, L Watterlot, O Lakhdari, LG Bermúdez-Humarán, ... Proceedings of the National Academy of Sciences 105 (43), 16731-16736, 2008 | 4972 | 2008 |
| Epidemiology and natural history of inflammatory bowel diseases J Cosnes, C Gower–Rousseau, P Seksik, A Cortot Gastroenterology 140 (6), 1785-1794. e4, 2011 | 2828 | 2011 |
| Low Counts of Faecalibacterium prausnitzii in Colitis Microbiota H Sokol, P Seksik, JP Furet, O Firmesse, I Nion-Larmurier, L Beaugerie, ... Inflammatory bowel diseases 15 (8), 1183-1189, 2009 | 1536 | 2009 |
| CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands B Lamas, ML Richard, V Leducq, HP Pham, ML Michel, G Da Costa, ... Nature medicine 22 (6), 598-605, 2016 | 1286 | 2016 |
| Fungal microbiota dysbiosis in IBD H Sokol, V Leducq, H Aschard, HP Pham, S Jegou, C Landman, D Cohen, ... Gut 66 (6), 1039-1048, 2017 | 1281 | 2017 |
| Predictors of Crohn’s disease L Beaugerie, P Seksik, I Nion–Larmurier, JP Gendre, J Cosnes Gastroenterology 130 (3), 650-656, 2006 | 1144 | 2006 |
| Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon P Seksik, L Rigottier-Gois, G Gramet, M Sutren, P Pochart, P Marteau, ... Gut 52 (2), 237-242, 2003 | 1006 | 2003 |
| Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases H Duboc, S Rajca, D Rainteau, D Benarous, MA Maubert, E Quervain, ... Gut 62 (4), 531-539, 2013 | 908 | 2013 |
| Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease E Quévrain, MA Maubert, C Michon, F Chain, R Marquant, J Tailhades, ... Gut 65 (3), 415-425, 2016 | 821 | 2016 |
| Specificities of the fecal microbiota in inflammatory bowel disease H Sokol, P Seksik, L Rigottier-Gois, C Lay, P Lepage, I Podglajen, ... Inflammatory bowel diseases 12 (2), 106-111, 2006 | 570 | 2006 |
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial P Marteau, M Lémann, P Seksik, D Laharie, JF Colombel, Y Bouhnik, ... Gut 55 (6), 842-847, 2006 | 545 | 2006 |
| Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease L Beaugerie, M Svrcek, P Seksik, AM Bouvier, T Simon, M Allez, H Brixi, ... Gastroenterology 145 (1), 166-175. e8, 2013 | 425 | 2013 |
| Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial M Rosenzwajg, R Lorenzon, P Cacoub, HP Pham, F Pitoiset, K El Soufi, ... Annals of the rheumatic diseases 78 (2), 209-217, 2019 | 378 | 2019 |
| Natural history of Crohn's disease: comparison between childhood-and adult-onset disease B Pigneur, P Seksik, S Viola, J Viala, L Beaugerie, JP Girardet, ... Inflammatory bowel diseases 16 (6), 953-961, 2010 | 346 | 2010 |
| Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD P Lepage, P Seksik, M Sutren, MF de La Cochetière, R Jian, P Marteau, ... Inflammatory bowel diseases 11 (5), 473-480, 2005 | 320 | 2005 |
| Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study H Sokol, C Landman, P Seksik, L Berard, M Montil, I Nion-Larmurier, ... Microbiome 8, 1-14, 2020 | 308 | 2020 |
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea‐predominant irritable bowel syndrome H Duboc, D Rainteau, S Rajca, L Humbert, D Farabos, M Maubert, ... Neurogastroenterology & Motility 24 (6), 513-e247, 2012 | 299 | 2012 |
| Probiotics and intestinal health effects: a clinical perspective P Marteau, P Seksik, R Jian British journal of Nutrition 88 (S1), s51-s57, 2002 | 287 | 2002 |
| Analysis of bacterial bowel communities of IBD patients: what has it revealed? H Sokol, C Lay, P Seksik, GW Tannock Inflammatory bowel diseases 14 (6), 858-867, 2008 | 281 | 2008 |
| Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease S Rajca, V Grondin, E Louis, G Vernier-Massouille, JC Grimaud, ... Inflammatory bowel diseases 20 (6), 978-986, 2014 | 269 | 2014 |
Harry SokolProfessor of Gastroenterology, St Antoine HospitalEmail verificata su aphp.fr